Drug Database · Clinicians

Fluticasone

Brands (27) Flixotide, Avamys, Flusort…Show all

US brand (reference label): XHANCE; not a Philippine-registered brand.

Corticosteroids (inflammation controllers); Glucocorticoid; and others PH FDA category

Rx · Prescription drug34 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 44fcea33-8cfa-3a5c-e063-6394a90aafb2, version date October 23, 2026 (XHANCE · Paratek Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.
  • Chronic rhinosinusitis without nasal polyps (CRSsNP) in adults.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE XHANCE is a corticosteroid indicated for the treatment of: Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. (1.1) Chronic rhinosinusitis without nasal polyps (CRSsNP) in adults. (1.2) 1.1 Chronic Rhinosinusitis with Nasal Polyps XHANCE is indicated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. 1.2 Chronic Rhinosinusitis without Nasal Polyps XHANCE is indicated for the treatment of chronic rhinosinusitis without nasal polyps (CRSsNP) in adults.

Contraindications

4 CONTRAINDICATIONS XHANCE is contraindicated in patients with hypersensitivity to any of the ingredients [see Warnings and Precautions (5.3) and Description (11)]. Hypersensitivity to any ingredient in XHANCE. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Recommended Dosage: 186 mcg (1 spray per nostril) or 372 mcg (2 sprays per nostril) twice daily. (2.1)
  • For nasal use only. Shake before use. Prime before initial use. (2.2)
  • XHANCE is delivered into the nose by actuating the pump spray into one nostril while simultaneously blowing into the mouthpiece of the device. (2.2)
2.1 Recommended Dosage

2.1 Recommended Dosage The recommended dosage of XHANCE is 186 mcg (1 spray per nostril) or 372 mcg (2 sprays per nostril) twice daily (total daily dose of 372 mcg or 744 mcg). The maximum total daily dosage should not exceed 2 sprays in each nostril twice daily (total daily dose of 744 mcg). Patients should use XHANCE at regular intervals since its effectiveness depends on regular use.

Individual patients will experience a variable time to onset and different degrees of symptom relief. The safety and efficacy of XHANCE when administered in excess of recommended doses have not been established.

2.2 Administration Information Shake

2.2 Administration Information Shake XHANCE before each use. Administer XHANCE by the nasal route only. Avoid spraying directly on the nasal septum. Priming Before initial use, prime XHANCE by first gently shaking and then pressing the bottle 7 times or until a fine mist appears. Direct the spray into the air, away from the face.

When XHANCE has not been used for ≥ 7 days, prime the pump again by shaking and releasing 2 sprays into the air, away from the face. Administration Instructions XHANCE is delivered into the nose by actuating the pump spray into one nostril while simultaneously blowing (exhaling) into the mouthpiece of the device. To administer XHANCE, insert the tapered tip of the cone-shaped nosepiece deep into one nostril and form a tight seal between the nosepiece and the nostril.

Next, place the flexible mouthpiece into the mouth, bending it as necessary to maintain a tight seal with the nostril. Blow into the mouthpiece, and while continuing to blow, push the bottle up to actuate the spray pump. Continuing to blow through the mouth, but not inhaling or exhaling through the nose, at the time of actuation is important to achieve intended drug deposition.

Repeat the process in the other nostril for a full dose [see Instructions for Use].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.7 Renal Impairment Formal pharmacokinetic trials using XHANCE have not been conducted in subjects with renal impairment.

Renal Impairment: Formal pharmacokinetic studies using XHANCE have not been conducted in patients with hepatic or renal impairment. However, since fluticasone propionate is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of fluticasone propionate in plasma. Therefore, patients with hepatic disease should be closely monitored. Racial or Ethnic Groups: No significant difference in clearance (CL/F) of fluticasone propionate in Caucasian, African-American, Asian, or Hispanic populations has been observed.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment Formal pharmacokinetic trials using XHANCE have not been conducted in subjects with hepatic impairment. Since fluticasone propionate is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of fluticasone propionate in plasma. Therefore, patients with hepatic disease should be closely monitored.

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of XHANCE in pediatric patients have not been established. Effects on Growth Controlled clinical trials have shown that nasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. This effect was observed in the absence of laboratory evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function.

The long-term effects of this reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with nasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving nasal corticosteroids should be monitored routinely (e.g., via stadiometry).

The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks associated with alternative therapies. Controlled clinical trials have shown that corticosteroids orally inhaled into the lungs may cause a reduction in growth in pediatric patients. In these trials, the mean reduction in growth velocity was approximately 1 cm/year (range: 0.3 to 1.8 cm/year) and appeared to depend upon dose and duration of exposure.

The effects on growth velocity of treatment with corticosteroids orally inhaled into the lungs for over 1 year, including the impact on final adult height, are unknown. The growth of children and adolescents receiving corticosteroids should be monitored routinely (e.g., via stadiometry) [see Warnings and Precautions (5.8)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical trials of XHANCE for Chronic Rhinosinusitis with Nasal Polyps did not include sufficient numbers of patients aged 65 years and older to determine whether they responded differently than younger patients. Other reported clinical experience with fluticasone administered nasally or orally inhaled has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

There were 82 patients 65 years of age and older in clinical trials for Chronic Rhinosinusitis without Nasal Polyps [see Clinical Studies (14)]. Of the total number of XHANCE-treated patients in these studies, 51 (14%) were 65 years of age and older. No overall differences in safety and effectiveness of XHANCE have been observed between patients 65 years of age and older and younger adult patients.

Administration

2.2 Administration Information Shake XHANCE before each use. Administer XHANCE by the nasal route only. Avoid spraying directly on the nasal septum. Priming Before initial use, prime XHANCE by first gently shaking and then pressing the bottle 7 times or until a fine mist appears. Direct the spray into the air, away from the face. When XHANCE has not been used for ≥ 7 days, prime the pump again by shaking and releasing 2 sprays into the air, away from the face. Administration Instructions XHANCE is delivered into the nose by actuating the pump spray into one nostril while simultaneously blowing (exhaling) into the mouthpiece of the device. To administer XHANCE, insert the tapered tip of the cone-shaped nosepiece deep into one nostril and form a tight seal between the nosepiece and the nostril. Next, place the flexible mouthpiece into the mouth, bending it as necessary to maintain a tight seal with the nostril. Blow into the mouthpiece, and while continuing to blow, push the bottle up to actuate the spray pump. Continuing to blow through the mouth, but not inhaling or exhaling through the nose, at the time of actuation is important to achieve intended drug deposition. Repeat the process in the other nostril for a full dose [see Instructions for Use ] .

US FDA label

Dosage forms

Philippines

  • Suspension for nasal spray: 27.5 mcg/actuation, 50 mcg/actuation, 500 mcg/mL, 500 mcg/mL (0.05 % w/v) 50 mcg per actuation
  • Nasal spray: 50 mcg, 50 mcg per actuation, 50 mcg/actuation
  • Aqueous nasal spray: 50 mcg, 50 mcg/actuation
  • Nasal spray suspension: 27.5 mcg, 27.5 mcg/actuation
  • ) suspension for nasal spray: 500 mcg/mL (50 mcg/0.1 mL
  • Metered dose inhaler: 50 mcg/Actuation, 125 mcg per actuation
  • Actuation aqueous nasal spray: 50 mcg
  • Aqueous suspension for inhalation: 50 mcg per actuation
  • Aqueous suspension. for inhalation: 50 mcg per actuation
  • Cream: 500 mcg/g

Registered products in the Philippines

34 products registered with the Food and Drug Administration (FDA) Philippines list Fluticasone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products34
Philippine FDA-registered products for Fluticasone
Package insert
AllertisFluticasone furoate
27.5 mcg Nasal Spray Suspension15 mL HDPE Bottle with metered dose pump, actustor and cap x 120 actuation (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt., Ltd.India
Medethix, Inc
DRP-17154
Oct 6, 2030
AvamysFluticasone Furoate
27.5 mcg/actuation Suspension for Nasal SprayGlass bottle fitted with a metering spray pump, encased in an off-white plastic device with a blue side-actuated lever and lid in 120, 60 and 30 actuations (Box of 1’s)
Rx
Glaxo Operations UK Ltd.United Kingdom
Importer: GlaxoSmithKline Philippines, Inc.
DR-XY35200
Dec 3, 2028
AvamysFluticasone Furoate
27.5 mcg/actuation Suspension for Nasal SprayType III amber glass bottle fitted with a metering spray pump encased in an off-white plastic device with a blue side-actuated lever and lid in 60 and 120 actuations (Box of 1's)
Rx
Glaxo Wellcome S.ASpain
Importer: GlaxoSmithKline Philippines, Inc.
DR-XY48797
Jun 30, 2028
CutivateFluticasone Propionate
500 mcg/g CreamAluminum Tube x 5 g Box of 1's
Rx
Glaxo Operations UK LimitedUnited Kingdom
Importer: GlaxoSmithKline Philippines Inc.
DR-XY20042
Oct 2, 2028
DalmanFluticasone propionate
50 mcg per actuation (0.05% w/w) Aqueous Suspension. for Inhalation (Nasal Spray)20 mL- capacity white HDPE bottle with crimp-on metered-dose micro pump, nasal actuator and dust protective cap x 120 actuations (Box of 1 bottle)
Rx
Drogsan Ilaclari Sanayi ve Ticaret A.S.Turkey
Orange Biotec Inc.
DRP-11996
May 27, 2027
FlixotideFluticasone Propionate
125 mcg per actuation Metered Dose inhalerMetal can with concave base fitted with a metering valve x 120 actuations (Box of 1's)
Rx
Glaxo Wellcome S.A.Spain
GlaxoSmithKline Philippines, Inc.
DR-XY23892
Sep 26, 2028
FlixotideFluticasone Propionate
50 mcg /Actuation Metered Dose InhalerAluminum Alloy Canister with Plastic Actuator x 120 Actuations
Rx
Glaxo Wellcome S.A.Spain
Importer: GlaxoSmithKline Philippines, Inc.
DR-XY27956
Oct 17, 2027
FlixotideFluticasone propionate
50 mcg/actuation Aqueous Nasal SprayType III Amber Glass Bottle fitted with metering atomising pump, nasal adaptor and dust cover (120 actuations) (Box of 1's)
Rx
Glaxo Wellcome S.ASpain
Importer: GlaxoSmithKline Philippines, Inc.
DR-XY15906
Apr 8, 2031
FlomistFluticasone Propionate
50 mcg actuation Aqueous Nasal Spray15 mL White Opaque HDPE Vial, fitted with Nasal Valve and Nasal Actuator (100 Actuations) (Box of 1's)
Rx
Cipla Ltd.India
RV Group Phil. Branch
DRP-12398
Aug 1, 2027
FlowFluticasone Propionate
500 mcg/mL Suspension for Nasal SprayUSP Type I Amber Glass Vial in 10 mL with nasal spray pump (Box of 1's)
Rx
Sava Healthcare LimitedIndia
All-Bio Pharma, Inc.Importer: Ambica International Corporation
DRP-6819-03
May 28, 2028
FLUMIST NSFluticasone Propionate
50 mcg Nasal SprayHDPE Bottle with Screw-on Nasal Spray Pump, Actuator and Cap x 15 mL Not Applicable
Rx
Biodeal Pharmaceuticals Ltd.India
Alkem Laboratories CorporationImporter: Greencore Pharma Inc.
DRP-18368-01
Jul 6, 2031
FlunaseFluticasone propionate
50 mcg/actuation (0.05% w/w) Aqueous Nasal SprayBrown Glass Bottle with 100 mcl (0.1mL) White Opaque HDPE Plastic Spray Pump Nozzle Sealed with Aluminum Ring & 23 mL x (Box of 1's)
Rx
Synmosa Biopharma Corporation, Synmosa PlantChina
Nurturemed Pharma Inc.
DR-XY49457
Jul 31, 2030
FlunexaFluticasone propionate
50 mcg per actuation nasal sprayGlass bottle with metered-dose manual pump x 120 actuations (Box of 1’s)
Rx
Jewim Pharmaceutical (Shandong) Co., Ltd.China
NextGen Pharmaceuticals Inc.
DRP-19165
Nov 11, 2031
FlusortFluticasone Propionate
50 mcg per actuation Nasal SprayHDPE Bottle crimped with nasal spray pump and fitted with an actuator and cap x 120 actuations (Box of 1's)
Rx
Glenmark Pharmaceuticals Ltd.India
Glenmark Philippines, Inc.
DR-XY44793
Mar 12, 2031
FlusortFluticasone Propionate
50 mcg per actuation Nasal SprayHDPE Bottle crimped with nasal spray pump and fitted with an actuator and cap x 120 actuations (Box of 1's)
Rx
Glenmark Pharmaceuticals Ltd.India
Glenmark Philippines, Inc.
DRP-17864
Mar 12, 2031
FlutelFluticasone Propionate
50 mcg Nasal Spray15 mL Type III Amber Glass Bottle with White Plastic 100 mcL Spray Pump and Nasal Spray Applicator Equipment with LDPE Natural Cap (Box of 1's)
Rx
World Medicine İlaç Sanayi Ve Ticaret A.Ş.Turkey
Pharma-Surrey International, Inc.
DRP-9077
Sep 15, 2031
Fluti NSFluticasone propionate
50 mcg per actuation (0.05% w/w) Aqueous Suspension for Inhalation (Nasal Spray)20 mL-capacity white HDPE bottle with crimp-on metered-dose micro pump, nasal actuator and dust protective cap x 120 actuations (Box of 1 bottle)
Rx
Drogsan Ilaclari Sanayi ve Ticaret A.S.Turkey
Preventia Healthcare Inc.Importer: Orange Biotec Inc.
DRP-11996-01
May 27, 2027
FlutiairFluticasone Propionate
500 mcg/mL (50 mcg/0.1 mL) Suspension for Nasal SprayUSP Type I Amber Glass Vial in 10 mL with Nasal Spray Pump (Box of 1's); USP Type I Amber Glass Vial in 12 mL with Nasal Spray Pump (Box of 1's)
Rx
Sava Healthcare LimitedIndia
Scheeling, Inc.Importer: Ambica International Corporation
DRP-6819
May 28, 2028
FlutilonFluticasone Propionate
500 mcg/mL (0.05% w/v) 50 mcg per actuation Suspension for Nasal SprayType I Amber Glass Bottle fitted with a white metering atomizing pump, white nasal adapter, and white dust cover in 120 actuations (Box of 1's)
Rx
Norris Medicines LimitedIndia
Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Private Limited
DRP-5411-01
Aug 1, 2029
Flutimate NSFluticasone Propionate
50 mcg/Actuation Suspension for Nasal SprayAmber Bottle with 120 Actuations x 15 mL (Box of 1's)
Rx
Jewim Pharmaceutical (Shandong) Co., Ltd.China
Healol Pharma Corporation
DRP-8066
Jul 21, 2029
FlutiridFluticasone Propionate
50 mcg / actuation (0.05 % w/v) Suspension for Nasal SprayWhite opaque HDPE plastic bottle with actuator and protection cap x 12 mL (120 actuations) (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt., Ltd.India
Kaufmann Pharma Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd.
DRP-14627-02
Nov 7, 2028
FlutirightFluticasone Propionate
500 mcg/mL (0.05% w/v) 50 mcg per actuation Suspension for Nasal Spray
Rx
Norris Medicines LimitedIndia
All-Bio Pharma, Inc.Importer: MedEthix Inc.Trader: Alvita Pharma Private Limited
DRP-5411
Feb 11, 2031
FlutiwindFluticasone Propionate
500 mcg/mL (50 mcg/0.1 mL) Suspension for Nasal SprayUSP Type I Amber Glass Vial in 10 mL with Nasal Spray Pump (Box of 1's)
Rx
Sava Healthcare LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-6819-04
May 28, 2028
FuxenovFluticasone Furoate
27.5 mcg/Actuation Nasal Spray Suspension15 mL White HDPE bottle with a metered dose pump Actuator and Dust Cap x 120 actuation (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt. Ltd..India
Medinova Pharmaceutical Inc.
DRP-18337
Jun 16, 2031
GratisFluticasone Propionate
50 mcg/ actuation (0.05% w/v) Suspension for Nasal SprayWhite opaque HDPE plastic bottled with actuator and protection cap x 12 mL (120 actuations) (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt., Ltd.India
Kaufmann Pharma Inc.Importer: Medethix, Inc.
DRP-14627-01
Nov 7, 2028
InflusaneFluticasone Propionate
50 mcg/actuation Nasal SprayWhite HDPE Bottle with Metered Dose Pump Actuator and PP Dust Cap x 15 mL (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-18334
Jun 15, 2031
NasobreatheFluticasone Propionate
50 mcg Nasal SprayHDPE Bottle with Screw-on Nasal Spray Pump, Actuator and Cap x 15 mL
Rx
BIODEAL PHARMACEUTICALS LTD.India
Greencore Pharma Inc.
DRP-18368
Jul 6, 2031
NasofloFluticasone Propionate
50 mcg Aqueous Nasal SprayAmber Glass Bottle (120 Sprays) in a box
Rx
Square Pharmaceuticals Ltd.Bangladesh
UNILAB, Inc.
DR-XY34848
Aug 28, 2028
NewflutFluticasone Propionate
500 mcg/mL Suspension for Nasal SprayUSP Type I Amber Glass Vial in 10 mL with nasal spray pump (Box of 1's)
Rx
Sava Healthcare LimitedIndia
I-Senz Medical Inc.Importer: Ambica International Corporation
DRP-6819-01
May 28, 2028
NoneFluticasone Propionate
500 mcg/mL Suspension for Nasal SprayUSP Type I Amber Glass Vial in 10 mL with nasal spray pump (Box of 1's)
Rx
Sava Healthcare LimitedIndia
Celsus Pharmaceuticals Phils., Inc.Importer: Ambica International Corporation
DRP-6819-02
May 28, 2028
ThixanaseFluticasone Propionate
50 mcg/actuation (0.05% w/v) Suspension for Nasal SprayWhite opaque HDPE plastic bottle with actuator and protection cap x 12 mL (120 actuations) (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt., LtdIndia
Medethix, Inc.
DRP-14627
Nov 7, 2028
TicanaseFluticasone
50 mcg/actuation (0.05% w/w) Nasal SprayUSP Type III Amber Glass Bottle and capped with Nasal Sprayer Head x 15 mL (Box of 1's)
Rx
European Egyptian Pharmaceutical Industries Co.Egypt
Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc.
DRP-15027
Mar 19, 2029
(no brand name)Fluticasone furoate
27.5 mcg/actuation Nasal Spray Suspension15 mL HDPE Bottle with metered doc FBA and cap x 120 actuation (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt., Ltd.India
Medethix, Inc
DRP-17155
Oct 6, 2030
(no brand name)Fluticasone Propionate
50 mcg/actuation (0.05% w/v) Suspension for Nasal SprayWhite opaque HDPE plastic bottle with actuator and protection cap x 12 mL (120 actuations) (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt., Ltd.India
Medethix, Inc
DRP-14533
Oct 4, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Nasal spray: Each spray delivers 93 mcg of fluticasone propionate. Nasal spray: 93 mcg of fluticasone propionate in each spray. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Local Nasal Adverse Reactions: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of adverse effects on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma. (5.1)
  • Glaucoma and Cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term. (5.2)
  • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur. (5.3)
  • Immunosuppression and Risk of Infection: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients. (5.4)
  • Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly. (5.5)
  • Assess for decrease in bone mineral density initially and periodically thereafter. (5.7)
5.1 Local Nasal Adverse Reactions Epistaxis, Nasal Erosions and Ulcerations

5.1 Local Nasal Adverse Reactions Epistaxis, Nasal Erosions and Ulcerations In placebo-controlled clinical trials of 16 weeks duration, epistaxis, nasal erosions, and nasal ulcerations were reported more frequently in patients treated with XHANCE than those who received placebo [see Adverse Reactions (6.1)]. Nasal Septal Perforation Nasal septal perforations have been reported in patients following the nasal application of XHANCE.

In placebo-controlled clinical trials of 16 weeks duration, nasal septal perforation was reported in 1 (0.3%) patient treated with XHANCE compared with none treated with placebo. The patient had a prior history of nasal/sinus surgery. Three (0.3%) patients treated with XHANCE in uncontrolled, open-label trials of 3 to 12 months duration developed nasal septal perforations.

As with any long term topical treatment of the nasal cavity, patients using XHANCE over several months or longer should be examined periodically for possible changes in the nasal mucosa. If a septal perforation is noted, discontinue XHANCE. Avoid spraying XHANCE directly on the septum. Candida Infection In clinical trials with XHANCE, localized infections with Candida albicans have been observed.

Eight (0.9%) patients in uncontrolled, open-label trials of 3 to 12 months duration developed Candida albicans infections (nasal, pharyngeal, esophageal or intestinal). If such an infection develops, it may require treatment with appropriate local therapy and discontinuation of XHANCE. Patients using XHANCE should be examined periodically for evidence of Candida infection in the nasal and oropharyngeal mucosa.

Impaired Wound Healing Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal ulcerations, nasal surgery, or nasal trauma should avoid using XHANCE until healing has occurred.

5.2 Glaucoma and Cataracts

5.2 Glaucoma and Cataracts Nasal and inhaled corticosteroids, including fluticasone propionate, may result in the development of glaucoma and/or cataracts. In placebo-controlled clinical trials of 16 weeks duration, cataracts were reported in 4 (1.2%) patients treated with XHANCE, compared with 3 (1.9%) patients treated with placebo.

Among these patients, 2 patients treated with XHANCE reported subcapsular cataracts compared with none treated with placebo. Eleven patients (1.2%) in uncontrolled, open-label trials of 3 to 12 months duration developed new or worsening cataracts, of which none were subcapsular. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure (IOP), glaucoma, and/or cataracts.

Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.

5.3 Hypersensitivity Reactions Including Anaphylaxis

5.3 Hypersensitivity Reactions Including Anaphylaxis Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. XHANCE is contraindicated in patients with known hypersensitivity to fluticasone propionate or any of the ingredients of XHANCE.

Discontinue XHANCE if such reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) occur [see Contraindications (4) and Adverse Reactions (6.1)].

5.4 Immunosuppression and Risk of Infection

5.4 Immunosuppression and Risk of Infection Persons who are using drugs that suppress the immune system, such as corticosteroids, including XHANCE, are more susceptible to infections than healthy individuals and may experience a worsening of existing infections. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible adults using corticosteroids.

In such adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.

If a patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective Prescribing Information for VZIG and IG.) If chickenpox develops, treatment with antiviral agents may be considered.

Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex [see Adverse Reactions (6.1)].

5.5 Hypercorticism and Adrenal Suppression

5.5 Hypercorticism and Adrenal Suppression Hypercorticism and adrenal suppression may occur when nasal corticosteroids, such as XHANCE, are used at higher than recommended dosages or in susceptible individuals at recommended dosages. Since fluticasone propionate is absorbed into the circulation and can be systemically active at higher doses, recommended dosages of XHANCE should not be exceeded to avoid hypothalamic-pituitary-adrenal (HPA) dysfunction.

A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortisol production has been shown after 4 weeks of pulmonary treatment with fluticasone propionate inhalation aerosol. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing XHANCE.

Patients treated with XHANCE should be observed carefully for any evidence of systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis). If such effects occur, the dosage of XHANCE should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids, and other treatments for management of nasal symptoms should be considered.

Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response. The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency. In addition, some patients may experience symptoms of corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression).

After withdrawal from systemic corticosteroids, a number of months are required for recovery of HPA function. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress such as trauma, surgery, infection (particularly gastroenteritis), or other conditions associated with severe electrolyte loss.

In patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, rapid decreases in systemic corticosteroid dosages may cause a severe exacerbation of their symptoms [see Adverse Reactions (6.1) and Clinical Pharmacology (12.2)].

5.6 Drug Interactions with Strong Cytochrome P450 3

5.6 Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole) with XHANCE is not recommended because increased systemic corticosteroid adverse effects may occur [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

5.7 Reduction in Bone Mineral Density

5.7 Reduction in Bone Mineral Density Decreases in bone mineral density (BMD) have been observed with long-term oral inhalation of products containing corticosteroids into the lungs. The clinical significance of small changes in BMD with regard to long-term consequences such as fracture is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care.

A 2-year trial in 160 patients (females aged 18 to 40 years, males aged 18 to 50 years) with asthma receiving chlorofluorocarbon (CFC)-propelled fluticasone propionate inhalation aerosol 88 or 440 mcg twice daily demonstrated no statistically significant changes in BMD at any time point (24, 52, 76, and 104 weeks of double-blind treatment) as assessed by dual-energy x-ray absorptiometry at lumbar regions L1 through L4.

5.8 Effect on Growth

5.8 Effect on Growth Nasal corticosteroids, including XHANCE, may cause a reduction in growth velocity when administered to pediatric patients. The safety and effectiveness of XHANCE has not been established in pediatric patients [see Use in Specific Populations (8.4)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects. (7.1) 7.1 Inhibitors of Cytochrome P450 3A4 Fluticasone propionate is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole) with XHANCE is not recommended because increased systemic corticosteroid adverse effects may occur.

Ritonavir A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations [see Clinical Pharmacology (12.3)]. During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving fluticasone propionate products with ritonavir, resulting in systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression.

Ketoconazole Coadministration of orally inhaled fluticasone propionate (1000 mcg) and ketoconazole (200 mg once daily) resulted in a 1.9-fold increase in plasma fluticasone propionate exposure and a 45% decrease in plasma cortisol area under the curve (AUC), but had no effect on urinary excretion of cortisol.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism : The only circulating metabolite detected in man is the 17β-carboxylic acid derivative of fluticasone propionate, which is formed through the CYP3A4 pathway.

Drug Interaction Studies Inhibitors of Cytochrome P450 3A4 Ritonavir : Fluticasone propionate is a substrate of CYP3A4.

Coadministration of fluticasone propionate and the strong CYP3A4 inhibitor, ritonavir, is not recommended based upon a multiple-dose, crossover drug interaction trial in 18 healthy subjects.

( 7.1 ) 7.1 Inhibitors of Cytochrome P450 3A4 Fluticasone propionate is a substrate of CYP3A4.

The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole) with XHANCE is not recommended because increased systemic corticosteroid adverse effects may occur.

Ritonavir A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations [see Clinical Pharmacology ( 12.3 )] .

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Local Nasal Adverse Reactions: [see Warnings and Precautions (5.1)] Glaucoma and Cataracts [see Warnings and Precautions (5.2)] Hypersensitivity Reactions including Anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.3)] Immunosuppression and Risk of Infection [see Warnings and Precautions (5.4)] Hypercorticism and Adrenal Suppression [see Warnings and Precautions (5.5)] Reduction in Bone Mineral Density [see Warnings and Precautions (5.7)] Effect on Growth [see Warnings and Precautions (5.8)] CRSwNP: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis. (6.1)
  • CRSsNP: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Paratek Pharmaceuticals, Inc. at 1-833-678-6673 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Chronic Rhinosinusitis with Nasal Polyps The safety data described below are based on two placebo-controlled clinical trials evaluating doses of a fluticasone propionate nasal spray with an exhalation delivery system from 93 mcg twice daily to 372 mcg twice daily.

Both trials were 16-weeks in duration with an additional 8-week open-label extension. The trials included a total of 643 adult patients with bilateral nasal polyps and associated moderate or severe nasal congestion of which 161 received 93 mcg twice daily, 160 received 186 mcg twice daily, 161 received 372 mcg twice daily and 161 received placebo.

The overall pooled safety data included 296 (46.0%) Female, 347 (54.0%) Male, 584 (90.8%) White, 39 (6.1%) Black, 9 (1.4%) Asian, and 11 (1.7%) patients classified as Other. Of these patients, 45 (7%) were 65 years of age or older. Table 1 displays adverse reactions with an incidence of ≥ 3% in the XHANCE 186 mcg and 372 mcg twice daily patients, and more common than placebo.

Table 1. Summary of Adverse Reactions with XHANCE Reported in ≥ 3% of Patients with CRSwNP and More Common Than Placebo in Placebo-Controlled Studies XHANCE Adverse Reaction Placebo (N = 161) n (%) 186 mcg bid* (N = 160) n (%) 372 mcg bid^ (N = 161) n (%) *186 mcg bid = 1 spray per nostril twice daily ^372 mcg bid = 2 sprays per nostril twice daily 1 Includes spontaneous adverse reaction reports 2 Include ulcerations and erosions Epistaxis 1 4 (2.5) 19 (11.9) 16 (9.9) Nasopharyngitis 8 (5.0) 3 (1.9) 12 (7.5) Nasal septal ulceration 2 3 (1.9) 11 (6.9) 12 (7.5) Nasal congestion 6 (3.7) 7 (4.4) 9 (5.6) Acute sinusitis 6 (3.7) 7 (4.4) 8 (5.0) Headache 5 (3.1) 8 (5.0) 6 (3.7) Pharyngitis 2 (1.2) 2 (1.3) 5 (3.1) Nasal mucosal ulceration 2 2 (1.3) 6 (3.8) 4 (2.5) Nasal mucosal erythema 6 (3.7) 9 (5.6) 8 (5.0) Nasal septal erythema 3 (1.9) 6 (3.8) 7 (4.3) Other adverse reactions with XHANCE observed with an incidence < 3% but ≥ 1% and more common than placebo included: nasal dryness, sinusitis, oropharyngeal pain, toothache, intraocular pressure increase, dizziness, abdominal discomfort, and weight increase. 5.0% of patients treated with XHANCE 186 mcg twice daily and 1.2% of patients treated with 372 mcg twice daily discontinued from the clinical trials prior to the open-label extension because of adverse reactions compared to 4.3% of patients treated with placebo.

There were no clinically relevant differences in the incidence of adverse reactions based on gender. Clinical trials did not include sufficient numbers of non-Caucasian patients or patients aged 65 years and older to determine whether they respond differently from Caucasian or younger patients, respectively. Chronic Rhinosinusitis without Nasal Polyps The safety of XHANCE was based on a pooled safety population that reflect the exposure of XHANCE in 367 adults with chronic rhinosinusitis with (CRSwNP) or without nasal polyps (CRSsNP) exposed for 24 weeks duration.

XHANCE was studied in two randomized, placebo-controlled, multicenter trials (Trial 3 and Trial 4). Patients received either XHANCE 186 mcg (1 spray per nostril) twice daily, XHANCE 372 mcg (2 sprays per nostril) twice daily, or placebo delivered with an exhalation delivery system. The pooled safety population had a mean age of 49 years [age range: 18 to 87], and were 55% male, 94% White, 96% non-Hispanic or Latino, 4% Black or African American, and 2% Asian.

In these trials, 1.6% of patients treated with XHANCE 186 mcg (1 spray per nostril) twice daily and 1.6% of patients treated with 372 mcg (2 sprays per nostril) twice daily discontinued treatment due to adverse reactions compared to 2.7% of patients treated with placebo. The most common adverse reactions that occurred at a rate of ≥ 3% in patients treated with XHANCE and at a higher rate in at least one treatment group than placebo from the pooled safety population (Trials 3 and 4) are shown in Table 2.

Table 2. Summary of Adverse Reactions with XHANCE Reported in ≥ 3% of Patients and More Common Than Placebo from Pooled Safety Population (Trials 3 and 4) 1 XHANCE Adverse Reaction Placebo (N = 187) n (%) 186 mcg bid* (N = 184) n (%) 372 mcg bid^ (N = 183) n (%) *186 mcg bid = 1 spray per nostril twice daily ^372 mcg bid = 2 sprays per nostril twice daily 1 Patients in Trial 3 included adults with CRSsNP and Trial 4 included adults with CRSsNP and CRSwNP Epistaxis 1 (0.5%) 9 (4.9%) 20 (10.9%) Headache 7 (3.7%) 4 (2.2%) 10 (5.5%) Nasopharyngitis 8 (4.3%) 9 (4.9%) 7 (3.8%)

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of XHANCE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye disorders: central serous chorioretinopathy Respiratory, thoracic, and mediastinal disorders: dysphonia, nasal discomfort, and nasal dryness Skin and subcutaneous tissue disorders: pruritus, rash

Adverse reaction frequency tables (US label) US FDA label
Table 1. Summary of Adverse Reactions with XHANCE Reported in ≥ 3% of Patients with CRSwNP and More Common Than Placebo in Placebo-Controlled Studies
XHANCE
Adverse Reaction Placebo (N = 161) n (%) 186 mcg bid* (N = 160) n (%) 372 mcg bid^ (N = 161) n (%)
*186 mcg bid = 1 spray per nostril twice daily ^372 mcg bid = 2 sprays per nostril twice daily 1Includes spontaneous adverse reaction reports 2Include ulcerations and erosions
Epistaxis 1 4 (2.5) 19 (11.9) 16 (9.9)
Nasopharyngitis 8 (5.0) 3 (1.9) 12 (7.5)
Nasal septal ulceration 2 3 (1.9) 11 (6.9) 12 (7.5)
Nasal congestion 6 (3.7) 7 (4.4) 9 (5.6)
Acute sinusitis 6 (3.7) 7 (4.4) 8 (5.0)
Headache 5 (3.1) 8 (5.0) 6 (3.7)
Pharyngitis 2 (1.2) 2 (1.3) 5 (3.1)
Nasal mucosal ulceration 2 2 (1.3) 6 (3.8) 4 (2.5)
Nasal mucosal erythema 6 (3.7) 9 (5.6) 8 (5.0)
Nasal septal erythema 3 (1.9) 6 (3.8) 7 (4.3)
Table 2. Summary of Adverse Reactions with XHANCE Reported in ≥ 3% of Patients and More Common Than Placebo from Pooled Safety Population (Trials 3 and 4) 1
XHANCE
Adverse Reaction Placebo (N = 187) n (%) 186 mcg bid* (N = 184) n (%) 372 mcg bid^ (N = 183) n (%)
*186 mcg bid = 1 spray per nostril twice daily ^372 mcg bid = 2 sprays per nostril twice daily 1Patients in Trial 3 included adults with CRSsNP and Trial 4 included adults with CRSsNP and CRSwNP
Epistaxis 1 (0.5%) 9 (4.9%) 20 (10.9%)
Headache 7 (3.7%) 4 (2.2%) 10 (5.5%)
Nasopharyngitis 8 (4.3%) 9 (4.9%) 7 (3.8%)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from published literature on the use of inhaled or nasal fluticasone propionate in pregnant women have not reported a clear association with adverse developmental outcomes. In animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight, and/or skeletal variations in rats, mice, and rabbits were observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the maximum recommended human daily inhaled dose (MRHDID) on a mcg/m 2 basis.

However, fluticasone propionate administered via inhalation to rats decreased fetal body weight, but did not induce teratogenicity at a maternal toxic dose less than the MRHDID on a mcg/m 2 basis (see Data). Experience with oral corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Animal Data In embryofetal development studies with pregnant rats and mice dosed by the subcutaneous route throughout the period of organogenesis, fluticasone propionate was teratogenic in both species. Omphalocele, decreased body weight, and skeletal variations were observed in rat fetuses, in the presence of maternal toxicity, at a dose approximately equivalent to the MRHDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 100 mcg/kg/day).

The rat no observed adverse effect level (NOAEL) was observed at approximately 0.4 times the MRHDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 30 mcg/kg/day). Cleft palate and fetal skeletal variations were observed in mouse fetuses at a dose approximately 0.3 times the MRHDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 45 mcg/kg/day).

The mouse NOAEL was observed with a dose approximately 0.1 times the MRHDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 15 mcg/kg/day). In an embryofetal development study with pregnant rats dosed by the inhalation route throughout the period of organogenesis, fluticasone propionate produced decreased fetal body weights and skeletal variations, in the presence of maternal toxicity, at a dose approximately 0.34 times the MRHDID (on a mcg/m 2 basis with a maternal inhalation dose of 25.7 mcg/kg/day); however, there was no evidence of teratogenicity.

The NOAEL was observed with a dose approximately 0.1 times the MRHDID (on a mcg/m 2 basis with a maternal inhalation dose of 5.5 mcg/kg/day). In an embryofetal development study in pregnant rabbits that were dosed by the subcutaneous route throughout organogenesis, fluticasone propionate produced reductions of fetal body weights, in the presence of maternal toxicity, at doses approximately 0.02 times the MRHDID and higher (on a mcg/m 2 basis with a maternal subcutaneous dose of 0.57 mcg/kg/day).

Teratogenicity was evident based upon a finding of cleft palate for 1 fetus at a dose approximately 0.1 times the MRHDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 4 mcg/kg/day). The NOAEL was observed in rabbit fetuses with a dose approximately 0.002 times the MRHDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 0.08 mcg/kg/day).

Fluticasone propionate crossed the placenta following subcutaneous administration to mice and rats and oral administration to rabbits. In a pre- and post-natal development study in pregnant rats dosed from late gestation through delivery and lactation (Gestation Day 17 to Postpartum Day 22), fluticasone propionate was not associated with decreases in pup body weight, and had no effects on developmental landmarks, learning, memory, reflexes, or fertility at doses up to 0.7 times the MRHDID (on a mcg/m 2 basis with maternal subcutaneous doses up to 50 mcg/kg/day).

Mechanism of action

12.1 Mechanism of Action Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide.

Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. The precise mechanism through which fluticasone propionate affects CRSsNP and CRSwNP and associated inflammatory symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation.

The anti-inflammatory action of corticosteroids contributes to their efficacy. In 7 trials in adults, fluticasone propionate nasal spray decreased nasal mucosal eosinophils in 66% of patients (35% for placebo) and basophils in 39% of patients (28% for placebo). In addition, studies suggest that carbon dioxide, which is present in the exhaled breath delivered into the nose through the device, may influence inflammatory mediator activity and neuropeptide activity, possibly through mechanisms of action that also include removal of nitric oxide, change in pH, or positive pressure.

The direct relationship of these findings to long-term symptom relief is not known.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics HPA Axis Effect The potential systemic effects of XHANCE on the HPA axis have not been evaluated. Serum cortisol concentrations, urinary excretion of cortisol, and urine 6-β- hydroxycortisol excretion collected over 24 hours in 24 healthy subjects following 8 oral inhalations of fluticasone propionate 44, 110, and 220 mcg decreased with increasing dose.

However, in patients with asthma treated with 2 oral inhalations of fluticasone propionate 44, 110, and 220 mcg twice daily for at least 4 weeks, differences in serum cortisol AUC 0-12h (n = 65) and 24-hour urinary excretion of cortisol (n = 47) compared with placebo were not related to dose and generally not significant. The potential systemic effects of orally inhaled fluticasone propionate on the HPA axis were also studied in subjects with asthma [see Warnings and Precautions (5.5) and Adverse Reactions (6)].

Fluticasone propionate given by oral inhalation aerosol at dosages of 440 or 880 mcg twice daily was compared with placebo in oral corticosteroid‑dependent subjects with asthma (range of mean dose of prednisone at baseline: 13 to 14 mg/day) in a 16-week trial. Consistent with maintenance treatment with oral corticosteroids, abnormal plasma cortisol responses to short cosyntropin stimulation (peak plasma cortisol less than 18 mcg/dL) were present at baseline in the majority of subjects participating in this trial (69% of subjects later randomized to placebo and 72% to 78% of subjects later randomized to fluticasone propionate HFA).

At week 16, 8 subjects (73%) on placebo compared with 14 (54%) and 13 (68%) subjects receiving fluticasone propionate HFA (440 and 880 mcg twice daily, respectively) had poststimulation cortisol levels of less than 18 mcg/dL. Cardiac Electrophysiology A study specifically designed to evaluate the effect of XHANCE on the QT interval has not been conducted.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination Following intravenous dosing, fluticasone propionate showed polyexponential kinetics and had a terminal elimination half-life of approximately 7.8 hours.

The total blood clearance of fluticasone propionate is high (average: 1093 mL/min), with renal clearance accounting for less than 0.02% of the total.

Excretion : Less than 5% of a radiolabeled oral dose was excreted in the urine as metabolites, with the remainder excreted in the feces as parent drug and metabolites.

Ketoconazole : Coadministration of fluticasone propionate orally inhaled into the lungs (1000 mcg) and ketoconazole (200 mg once daily) resulted in a 1.9-fold increase in plasma fluticasone propionate exposure and a 45% decrease in plasma cortisol AUC, but had no effect on urinary excretion of cortisol.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The activity of XHANCE is due to the parent drug, fluticasone propionate. Due to the low bioavailability by the nasal route, the majority of the pharmacokinetic data were obtained via other routes of administration. Absorption The mean (SD) peak exposure (C max) and total exposure (AUC 0-∞) following administration of a dose of 186 mcg of XHANCE during exhalation were 17.2 ± 7.40 pg/mL and 111.7 ± 49.75 pg·h/mL, respectively, and were 25.3 ± 10.34 pg/mL and 171.7 ± 85.55 pg·h/mL, respectively, following a dose of 372 mcg of XHANCE in healthy subjects.

The C max and AUC 0-∞ following a dose of 372 mcg of XHANCE in patients with mild to moderate asthma were 28.7±18.72 pg/mL and 222.6±84.60 pg·h/mL, respectively. Distribution Following intravenous administration, the initial disposition phase for fluticasone propionate was rapid and consistent with its high lipid solubility and tissue binding.

The volume of distribution averaged 4.2 L/kg. The percentage of fluticasone propionate bound to human plasma proteins averaged 99%. Fluticasone propionate is weakly and reversibly bound to erythrocytes and is not significantly bound to human transcortin. Local exposure within the nasal cavity with XHANCE will differ when used without exhalation through the device.

Elimination Following intravenous dosing, fluticasone propionate showed polyexponential kinetics and had a terminal elimination half-life of approximately 7.8 hours. The total blood clearance of fluticasone propionate is high (average: 1093 mL/min), with renal clearance accounting for less than 0.02% of the total. Metabolism: The only circulating metabolite detected in man is the 17β-carboxylic acid derivative of fluticasone propionate, which is formed through the CYP3A4 pathway.

This metabolite had less affinity (approximately 1/2000) than the parent drug for the glucocorticoid receptor of human lung cytosol in vitro and negligible pharmacological activity in animal studies. Other metabolites detected in vitro using cultured human hepatoma cells have not been detected in man. Excretion: Less than 5% of a radiolabeled oral dose was excreted in the urine as metabolites, with the remainder excreted in the feces as parent drug and metabolites.

Specific Populations XHANCE was not studied in any special populations, and no gender-specific pharmacokinetic data have been obtained. Pediatric Patients: XHANCE was not studied in pediatric patients, and no pediatric-specific pharmacokinetic data have been obtained with the product. Patients with Hepatic and Renal Impairment: Formal pharmacokinetic studies using XHANCE have not been conducted in patients with hepatic or renal impairment.

However, since fluticasone propionate is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of fluticasone propionate in plasma. Therefore, patients with hepatic disease should be closely monitored. Racial or Ethnic Groups: No significant difference in clearance (CL/F) of fluticasone propionate in Caucasian, African-American, Asian, or Hispanic populations has been observed.

Drug Interaction Studies Inhibitors of Cytochrome P450 3A4 Ritonavir: Fluticasone propionate is a substrate of CYP3A4. Coadministration of fluticasone propionate and the strong CYP3A4 inhibitor, ritonavir, is not recommended based upon a multiple-dose, crossover drug interaction trial in 18 healthy subjects. Fluticasone propionate aqueous nasal spray (200 mcg once daily) was coadministered for 7 days with ritonavir (100 mg twice daily).

Plasma fluticasone propionate concentrations following fluticasone propionate aqueous nasal spray alone were undetectable (< 10 pg/mL) in most subjects, and when concentrations were detectable, peak levels (C max) averaged 11.9 pg/mL (range: 10.8 to 14.1 pg/mL) and AUC 0-τ averaged 8.43 pg·h/mL (range: 4.2 to 18.8 pg·h/mL). Fluticasone propionate C max and AUC 0-τ increased to 318 pg/mL (range: 110 to 648 pg/mL) and 3102.6 pg·h/mL (range: 1207.1 to 5662.0 pg·h/mL), respectively, after coadministration of ritonavir with fluticasone propionate aqueous nasal spray.

This significant increase in plasma fluticasone propionate exposure resulted in a significant decrease (86%) in serum cortisol AUC. Ketoconazole: Coadministration of fluticasone propionate orally inhaled into the lungs (1000 mcg) and ketoconazole (200 mg once daily) resulted in a 1.9-fold increase in plasma fluticasone propionate exposure and a 45% decrease in plasma cortisol AUC, but had no effect on urinary excretion of cortisol.

Following orally-inhaled fluticasone propionate alone, AUC 2-last averaged 1559 pg·h/mL (range: 555 to 2906 pg·h/mL) and AUC 2-∞ averaged 2269 pg·h/mL (range: 836 to 3707 pg·h/mL). Fluticasone propionate AUC 2-last and AUC 2-∞ increased to 2781 pg·h/mL (range: 2489 to 8486 pg·h/mL) and 4317 pg·h/mL (range: 3256 to 9408 pg·h/mL), respectively, after coadministration of ketoconazole with orally-inhaled fluticasone propionate.

This increase in plasma fluticasone propionate concentration resulted in a decrease (45%) in serum cortisol AUC. Erythromycin: In a multiple-dose drug interaction study, coadministration of orally inhaled fluticasone propionate (500 mcg twice daily) and erythromycin (333 mg 3 times daily) did not affect fluticasone propionate pharmacokinetics.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Fluticasone 0.05% dose x 120 doses Nasal Aqueous Solution₱247.79Reference ₱247.79per unitDPRI procurement range
Fluticasone 50 mcg/dose x 120 doses Metered Dose Inhaler₱160.88Reference ₱160.88per inhalerDPRI procurement range
Fluticasone 125 mcg/dose x 120 doses Metered Dose Inhaler₱178.90–₱215.82Reference ₱178.90per inhalerDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Fluticasone (as propionate)
PNF listingNasal Aqueous Solution: 0.05%/dose x 120 doses Inhalation:
PNF listingDPI: 50 micrograms/dose with appropriate accompanying dispenser
PNF listingDPI: 250 micrograms/dose with appropriate accompanying dispenser
PNF listingMDI: 50 micrograms/dose x 60 doses and 120 doses
PNF listingMDI: 125 micrograms/dose x 60 doses and 120 doses
PNF listingResp. Soln.: (for nebulization) 250 micrograms/mL, 2 mL (unit dose)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. XHANCE · Paratek Pharmaceuticals, Inc. [US FDA-approved label, version 3, October 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44fcea33-8cfa-3a5c-e063-6394a90aafb2
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .